 The objective of this study was to evaluate the efficacy and safety of the dual SGLT1 and SGLT2 inhibitor sotagliflozin compared with placebo when combined with optimized insulin in adults with type 1 diabetes ( T1D). In a double-blind , 52-week , international phase 3 trial , adults with T1D were randomized to placebo ( At 24 weeks , placebo-adjusted changes in HbA In a 1-year study , sotagliflozin was associated with statistically significant HbA